A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark

References

• International Diabetes Federation. Diabetes in Denmark. 2015. http://www.idf.org/membership/eur/denmark. Brussels, Belgium. Accessed June 10, 2016
   Google Scholar
• Sortsø C, Green A, Jensen PB, et al. Societal costs of diabetes mellitus in Denmark. Diabet Med 2016;33:877-85
   PubMed Web of Science ®Google Scholar
• Brod M, Christensen T, Thomsen TL, et al. The impact of non-severe hypoglycemic events on work productivity and diabetes management. Value Health 2011;14:665-71
   PubMed Web of Science ®Google Scholar
• Haahr H, Heise T. A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin Pharmacokinet 2014;53:787-800
   PubMed Web of Science ®Google Scholar
• Meneghini L, Atkin SL, Gough SC, et al. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes. Diabetes Care 2013;36:858-64
   PubMed Web of Science ®Google Scholar
• Mathieu C, Hollander P, Miranda-Palma B, et al. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab 2013;98:1154-62
   PubMed Web of Science ®Google Scholar
• Kadowaki T, Jinnouchi H, Kaku K, et al. Efficacy and safety of once-daily insulin degludec dosed flexibly at convenient times vs fixed dosing at the same time each day in a Japanese cohort with type 2 diabetes: A randomized, 26-week, treat-to-target trial. J Diabetes Investig 2016;7:711-17
   PubMed Web of Science ®Google Scholar
• Vora J, Christensen T, Rana A, et al. Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trials. Diabetes Ther 2014;5:435-46
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004;20(Suppl 1):S5-S26
   PubMed Web of Science ®Google Scholar
• Clarke PM, Gray AM, Briggs A, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) outcomes model (UKPDS no. 68). Diabetologia 2004;47:1747-59
   PubMed Web of Science ®Google Scholar
• Ericsson Å, Pollock RF, Hunt B, et al. Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden. J Med Econ 2013;16:1442-52
   PubMedGoogle Scholar
• Evans M, Wolden M, Gundgaard J, et al. Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin - from the UK health care cost perspective. Diabetes Obes Metab 2014;16:366-75
   PubMed Web of Science ®Google Scholar
• Evans M, Wolden M, Gundgaard J, et al. Cost-effectiveness of insulin degludec compared with insulin glargine in a basal-bolus regimen in patients with type 1 diabetes mellitus in the UK. J Med Econ 2015;18:56-68
   PubMed Web of Science ®Google Scholar
• Donaldson C, Baker R, Mason H, et al. European value of a quality adjusted life year. Newcastle, UK: Newcastle University, 2010. http://research.ncl.ac.uk/eurovaq/EuroVaQ_Final_Publishable_Report_and_Appendices.pdf. Accessed June 10, 2016
   Google Scholar
• Östenson CG, Geelhoed-Duijvestijn P, Lahtela J, et al. Self-reported non-severe hypoglycaemic events in Europe. Diabet Med 2014;31:92-101
   PubMed Web of Science ®Google Scholar
• Jensen MM, Pedersen-Bjergaard U. Self-reported frequency and impact of non-severe hypoglycemic events in insulin-treated diabetic patients in Denmark. Diabetes Manag 2015;5:67-78
   Google Scholar
• Pedersen-Bjergaard U, Kristensen PL, Nørgaard K, et al. Short-term cost-effectiveness of insulin detemir and insulin aspart in people with type 1 diabetes who are prone to recurrent severe hypoglycemia. Curr Med Res Opin 2016;20:1-7
   Google Scholar
• Bilde L. International sammenligning af akut ambulancetjeneste. En foranalyse vedrørende finansieringsmæssige og økonomiske aspekter. Copenhagen, Denmark: KORA. Det Nationale Institut for Kommuners og Regioners Analyse og Forskning, December 2003. http://www.kora.dk/media/529721/dsi-1422.pdf. Accessed February 2016
   Google Scholar
• Danmarks Statistik. Forbrugerprisindeks. Copenhagen, Denmark: Danmarks Statistik, 2016. http://dst.dk/da/Statistik/emner/forbrugerpriser/forbrugerprisindeks. Accessed February 2016
   Google Scholar
• The Danish Health Data Authority. DRG-takster 2015: DAGS BG50A charge. Copenhagen, Denmark, 2015. http://sundhedsdatastyrelsen.dk/da/afregning-og-finansiering/takster-drg/takster-2015. Accessed February 2016
   Google Scholar
• Hatting NP, Mikkelsen S. Treatment of hypoglycaemic diabetics in a prehospital setting is safe. Dan Med J 2015;62:A5044
   PubMed Web of Science ®Google Scholar
• The Danish Health Data Authority. DRG-takster 2015: DAGS SP12D charge. Copenhagen, Denmark, 2015. http://sundhedsdatastyrelsen.dk/da/afregning-og-finansiering/takster-drg/takster-2015. Accessed February 2016
   Google Scholar
• Lyngsie PJ, Lopes S, Olsen J. Incidence and cost of hypoglycemic events requiring medical assistance in a hospital setting in Denmark. J Comp Eff Res 2016;5:239-47
   PubMed Web of Science ®Google Scholar
• Praktiserende Lægers Organisation, Honorarium § 50 Grundydelser (dagtid), Telefonkonsultation 0201. Copenhagen, Denmark, 2016. http://www.laeger.dk/portal/page/portal/LAEGERDK/Laegerdk/P_L_O/Overenskomster/Honorartabel/. Accessed February 2016
   Google Scholar
• Heller SR, Frier BM, Hersløv ML, et al. Severe hypoglycaemia in adults with insulin-treated diabetes: impact on healthcare resources. Diabet Med 2016;33:471-7
   PubMed Web of Science ®Google Scholar
• Söderqvist I, Landstedt-Hallin L, Lins P. Byte från 1-dos till 2-dosadministrering av insulin glargin hos patienter med typ 1-diabetes på diabetesmottagningen vid Danderyds sjukhus, en retrospektiv observationsstudie. Abstract presented at the Annual General Meeting for Physicians, November 25–27, 2010, Stockholm, Sweden
   Google Scholar
• Novo Nordisk. Data on File. Presentation: Afdækning af dosisproblematikken: Levemir – Lantus. Copenhagen, Denmark, 2014
   Google Scholar
• Allbright ES, Desmond R, Bell DS. Efficacy of conversion from bedtime NPH insulin injection to once- or twice-daily injections of insulin glargine in type 1 diabetic patients using basal/bolus therapy. Diabetes Care 2004;27:632-3
   PubMed Web of Science ®Google Scholar
• Garg SK, Gottlieb PA, Hisatomi ME, et al. Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine. Diabetes Res Clin Pract 2004;66:49-56
   PubMed Web of Science ®Google Scholar
• Delgado E, LAUREL Spain study investigators. Outcomes with insulin glargine in patients with type 2 diabetes previously on NPH insulin: evidence from clinical practice in Spain. Int J Clin Pract 2012;66:281-8
   PubMed Web of Science ®Google Scholar
• Lauridsen JT, Lønborg J, Gundgaard J, et al. Diminishing marginal disutility of hypoglycaemic events: results from a time trade-off survey in five countries. Qual Life Res 2014;23:2645-50
   PubMed Web of Science ®Google Scholar
• Evans M, Khunti K, Mamdani M, et al. Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries. Health Qual Life Outcomes 2013;11:90
   PubMed Web of Science ®Google Scholar
• Holstein A, Plaschke A, Vogel MY, et al. Prehospital management of diabetic emergencies—a population-based intervention study. Acta Anaesthesiol Scand 2003;47:610-15
   PubMed Web of Science ®Google Scholar
• Danish Health Authority (Sundhedsstyrelsen), Tal på diabetes 1996–2012; Copenhagen, Denmark: Danish Health Authority, 2013. http://www.diabetes.dk/
   Google Scholar
• Bech TH. Diabetikere med pumpe har markant mindre risiko for at dø. 2015. Jyllands-Posten. Copenhagen, Denmark. Available from: http://jyllands-posten.dk/livsstil/familiesundhed/sundhed/ECE7863923/Diabetikere-med-pumpe-har-markant-mindre-risiko-for-at-dø/ Accessed October 2016
   Google Scholar
• Statens Serum Institute. Dataleverancer og Lægemiddelstatistik [Data Supplies and Medicines Statistics]. Copenhagen, Denmark. 2013. http://medstat.dk/ Accessed October 2016
   Google Scholar
• Evans M, Jensen HH, Bøgelund M, et al. Flexible insulin dosing improves health-related quality-of-life (HRQoL): a time trade-off survey. J Med Econ 2013;16:1357-65
   PubMedGoogle Scholar
• Philis-Tsimikas A, Brod M, Niemeyer M, et al. Insulin degludec once-daily in Type 2 diabetes: simple or step-wise titration (BEGIN: once simple use). Adv Ther 2013;30:607-22
   PubMed Web of Science ®Google Scholar
• Rolving N, Sogaard R, Nielsen CV, et al. Preoperative cognitive-behavioral patient education versus standard care for lumbar spinal fusion patients: economic evaluation alongside a randomized controlled trial. Spine 2016;41:18-25
   PubMed Web of Science ®Google Scholar
• Hastrup LH, Kronborg C, Bertelsen M, et al. Cost-effectiveness of early intervention in first-episode psychosis: economic evaluation of a randomised controlled trial (the OPUS study). Br J Psychiatry 2013;202:35-41
   PubMed Web of Science ®Google Scholar
• Oddershede L, Riahi S, Nielsen JC, et al. Health economic evaluation of single-lead atrial pacing vs dual-chamber pacing in sick sinus syndrome. Europace 2014;16:866-72
   PubMed Web of Science ®Google Scholar
• Ehlers L, Overvad K, Sørensen J, et al. Analysis of cost effectiveness of screening Danish men aged 65 for abdominal aortic aneurysm. BMJ 2009;338:b2243
   PubMedGoogle Scholar
• Lane W, Bailey TS, Gerety G, et al. SWITCH 1: reduced hypoglycaemia with insulin degludec (IDeg) vs insulin glargine (IGLar, both U100, in patients with T1D at high risk of hypoglycaemia: a randomized, double-blind, crossover trial. 76th American Diabetes Association Congress, New Orleans, LA, United States. June 10–14, 2016
   Google Scholar
• Wysham CH, Bhargava AJ, Chaykin LB, et al. SWITCH 2: Reduced hypoglycaemia with insulin degludec (IDeg) vs insulin Glargine (IGlar), both U100, in patients with T2D at high risk of hypoglycaemia: a randomized, double-blind, cross-over trial. 76th American Diabetes Association Congress, New Orleans, LA, United States. June 10–14, 2016
   Google Scholar